ONS ONCC Chemo Renewal
Practice Test QUESTIONS &
ANSWERS | A+ GRADED 100%
VERIFIED – Full Study Pack
• A comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation to
assess life expectancy and risk of morbidity and mortality in the older patient. This
assessment tool would evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN Older Adult
Oncology Guidelines, version 1.2015). . Answer: Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric assessment. You
know that this assessment covers all but which of the following:
• 65 . Answer: The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric assessment.
Currently, more than 60% of cancers in the United States occur in people age
______and older and as the oncology world ages, nearly half (46%) of cancer
survivors are 70 years of age or older
• Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive are
categorized as irritants. Docetaxel can cause a significant reaction if it extravasates.
It can lead to edema, erythema, occasional pain and blister formation (ONS
Chemo/Bio guidelines, 2014). That is the most likely reason that Mrs. Turner was
given a port for her treatments. Some patients will receive their treatments through
a peripheral IV without incident. Just because they are intravenous agents does not
mean that a port is required and needing a port has nothing to do with her being
older in age. Since none of these agents are vesicants, they likely could have been
given safely via peripheral route but having a port placed is OK as well. . Answer:
,What is your best explanation for why Mrs. Turner was given a port to receive her
chemotherapy?
• Irrirtants . Answer: _____________can cause inflammation, pain, and burning
but rarely cause tissue necrosis comparable to a vesicant (unless a large amount or
a very high concentration of the irritant is extravasated).
• Vesicants . Answer: _____________can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
• Non-DNA-binding solutions remain in the local area of the extravasation, which
improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist to be
ingested cellularly, leading to progressive tissue destruction . Answer: A further
classification of an antineoplastic agent's potential to cause damage is whether its
mechanism of action includes DNA binding.
• Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin . Answer: DNA Binding Irritants
• Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine . Answer: DNA Nonbinding vessicants
• Sodium thiosulfate
, Inject 2 ml of sodium thiosulfate for each milligram of
mechlorethamine extravasated.
Inject subcutaneously into extravasation site using a 25
gauge or smaller needle (change needle with each injection).
Monitor extravasation site according to the institution's
policies and procedures. . Answer: Extravasciation Alkylating / Mechlorethamine
tx
• Apply warm compresses.
Dexamethasone
8 mg twice daily
for 14 days . Answer: Extravasciation Alkylating: Oxaliplatin
• Totect
Apply ice pack (remove 15
minutes prior to Totect
treatment).
Infusion should be initiated within six hours of extravasation.
Infused over 1-2 hours for three days in an area other
than the extravasation site
The dose recommended is based on the patients' body
surface area.
• Day 1: 1,000 mg/m2
• Day 2: 1,000 mg/m2
• Day 3: 500 mg/m . Answer: Extravasation Tx: Anthracyclines --- Daunorubicin,
doxorubicin, epirubicin,
idarubicin
• Hyaluronidase
Apply warm pack for
15-20 minutes four times
daily the next 24-48
Practice Test QUESTIONS &
ANSWERS | A+ GRADED 100%
VERIFIED – Full Study Pack
• A comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation to
assess life expectancy and risk of morbidity and mortality in the older patient. This
assessment tool would evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN Older Adult
Oncology Guidelines, version 1.2015). . Answer: Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric assessment. You
know that this assessment covers all but which of the following:
• 65 . Answer: The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric assessment.
Currently, more than 60% of cancers in the United States occur in people age
______and older and as the oncology world ages, nearly half (46%) of cancer
survivors are 70 years of age or older
• Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive are
categorized as irritants. Docetaxel can cause a significant reaction if it extravasates.
It can lead to edema, erythema, occasional pain and blister formation (ONS
Chemo/Bio guidelines, 2014). That is the most likely reason that Mrs. Turner was
given a port for her treatments. Some patients will receive their treatments through
a peripheral IV without incident. Just because they are intravenous agents does not
mean that a port is required and needing a port has nothing to do with her being
older in age. Since none of these agents are vesicants, they likely could have been
given safely via peripheral route but having a port placed is OK as well. . Answer:
,What is your best explanation for why Mrs. Turner was given a port to receive her
chemotherapy?
• Irrirtants . Answer: _____________can cause inflammation, pain, and burning
but rarely cause tissue necrosis comparable to a vesicant (unless a large amount or
a very high concentration of the irritant is extravasated).
• Vesicants . Answer: _____________can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
• Non-DNA-binding solutions remain in the local area of the extravasation, which
improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist to be
ingested cellularly, leading to progressive tissue destruction . Answer: A further
classification of an antineoplastic agent's potential to cause damage is whether its
mechanism of action includes DNA binding.
• Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin . Answer: DNA Binding Irritants
• Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine . Answer: DNA Nonbinding vessicants
• Sodium thiosulfate
, Inject 2 ml of sodium thiosulfate for each milligram of
mechlorethamine extravasated.
Inject subcutaneously into extravasation site using a 25
gauge or smaller needle (change needle with each injection).
Monitor extravasation site according to the institution's
policies and procedures. . Answer: Extravasciation Alkylating / Mechlorethamine
tx
• Apply warm compresses.
Dexamethasone
8 mg twice daily
for 14 days . Answer: Extravasciation Alkylating: Oxaliplatin
• Totect
Apply ice pack (remove 15
minutes prior to Totect
treatment).
Infusion should be initiated within six hours of extravasation.
Infused over 1-2 hours for three days in an area other
than the extravasation site
The dose recommended is based on the patients' body
surface area.
• Day 1: 1,000 mg/m2
• Day 2: 1,000 mg/m2
• Day 3: 500 mg/m . Answer: Extravasation Tx: Anthracyclines --- Daunorubicin,
doxorubicin, epirubicin,
idarubicin
• Hyaluronidase
Apply warm pack for
15-20 minutes four times
daily the next 24-48
